ASTELLAS PHARMA
🇯🇵Japan
- Country
- 🇯🇵Japan
- Ownership
- -
- Established
- 2005-01-01
- Employees
- -
- Market Cap
- $22.5B
- Website
- https://www.astellas.com/
A Study to Assess the Safety and Efficacy of ASP1941 in Combination With Dipeptidyl Peptidase-4 (DPP-4) Inhibitor in Type 2 Diabetic Patients
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2010-11-16
- Last Posted Date
- 2024-11-08
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 106
- Registration Number
- NCT01242228
A Study to Assess the Efficacy and Safety of ASP1941 in Combination With Sulfonylurea in Type 2 Diabetic Patients
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2010-11-16
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 243
- Registration Number
- NCT01242215
A Study of the Effect of ASP1941 on Cardiac Repolarization in Healthy Subjects
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2010-11-02
- Last Posted Date
- 2011-02-28
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 88
- Registration Number
- NCT01232413
A Study to Determine the Maximum Tolerated Dose of ASG-5ME in Subjects With Castration-Resistant Prostate Cancer
- First Posted Date
- 2010-10-26
- Last Posted Date
- 2013-06-07
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 46
- Registration Number
- NCT01228760
- Locations
- 🇺🇸
The Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States
🇺🇸University of Wisconsin Madison, Carbone Cancer Center, Madison, Wisconsin, United States
🇺🇸The Karmanos Cancer Institute, Detriot, Michigan, United States
A Study to Evaluate the Efficacy of Tacrolimus in Rheumatoid Arthritis Patients Shown Unsuccessful Response to Methotrexate
- First Posted Date
- 2010-10-20
- Last Posted Date
- 2010-10-20
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 50
- Registration Number
- NCT01224418
A Study to Assess the Efficacy and Safety of ASP1941 in Combination With Pioglitazone in Type 2 Diabetic Patients
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2010-10-20
- Last Posted Date
- 2024-11-11
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 152
- Registration Number
- NCT01225081
Single and Multiple Oral Administration Study of ASP015K in Healthy Nonelderly Volunteers
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2010-10-20
- Last Posted Date
- 2024-10-16
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 72
- Registration Number
- NCT01225224
A Study to Evaluate Efficacy of Ramosetron on Diarrhea-predominant Irritable Bowel Syndrome (IBS) in Male Patients
- First Posted Date
- 2010-10-20
- Last Posted Date
- 2014-10-15
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 296
- Registration Number
- NCT01225237
A Study to Evaluate the Efficacy and Safety of Tacrolimus in Korean Nephropathy Patients
- First Posted Date
- 2010-10-19
- Last Posted Date
- 2014-08-21
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 40
- Registration Number
- NCT01224028
Study to Evaluate the Efficacy of Tacrolimus in Rheumatoid Arthritis Patients Shown Unsuccessful Response to Methotrexate
- First Posted Date
- 2010-10-19
- Last Posted Date
- 2015-12-29
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 78
- Registration Number
- NCT01224041
© Copyright 2024. All Rights Reserved by MedPath